5 results

• Zinbryta Brain Inflammation Risks Outweigh Benefits: EMA

  May 22, 2018

  Irvin Jackson

  European regulators say they have positively confirmed that the recently recalled MS drug Zinbryta had health risks that outweighed any potential benefits, indicating that causes of severe brain inflammation were impossible to predict.

• Zinbryta Risks Prevented Use As MS Drug, Despite Effectiveness of Treatment: Report

  April 25, 2018

  Irvin Jackson

  A new study indicates that Zinbryta side effects were so severe it could have never become a major drug product, raising questions as to why it was approved when there were less dangerous alternatives.

• Zinbryta Withdrawal from U.S. Market to Be Complete April 30

  March 21, 2018

  Irvin Jackson

  The FDA says it will help multiple sclerosis patients transition to other drugs following a Zinbryta recall, and will let it stay on the market until the end of April.

• Zinbryta Deaths, Brain Inflammation Problems Lead to Global Market Withdraw for MS Drug

  March 9, 2018

  Irvin Jackson

  A Zinbryta recall has been announced following 12 cases of brain inflammation, including three deaths, linked to use of the multiple sclerosis drug.

• Zinbryta Recall Recommended by European Regulators, Following Reports Of Encephalitis, Patient Deaths

  March 8, 2018

  Irvin Jackson

  A Zinbryta recall and ban has been recommended in the EU following a dozen reports of serious brain inflammation linked to at least three patient deaths.